Charles Sweet - Response Oncology President CEO
CEO
Mr. Sweet, age 46, joined the Company as President and Chief Executive Officer in April 2002. Prior to joining Response Oncology, Inc., he served as President and Chief Executive Officer of Physician Health Corporationrationration, a PPM specializing in radiation oncology and comprehensive cancer treatment from October 2000 until April 2002. From December 1998 until January 2000 he served as President and Chief Executive Officer and from May 1998 to December 1998 as Chief Operating Officer and Chief Information Officer of BMJ Medical Management, Inc., a PPM specializing in orthopedics. From 1984 until May 1998, Mr. Sweet held several positions including Chief Operating Officer, Chief Information Officer, and Regional Vice President with Mercy Health Services, a large, notforprofit health care system located in the Midwest. Mr. Sweet was Chairman of the Board of Sarcom, a value added reseller of computer equipment and services, since October 2001. In addition, he has served as a director with BMK Inc., a wholesale distributor of grocery and drug store products since March 2002, and sole director of Rehab Designs of America, a prosthetics and orthotics company, since December 2001. since 2002.
| Age | 66 |
| Tenure | 22 years |
| Phone | 901-761-7000 |
Response Oncology Management Efficiency
The company has return on total asset (ROA) of (0.0153) % which means that it has lost $0.0153 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2393) %, meaning that it created substantial loss on money invested by shareholders. Response Oncology's management efficiency ratios could be used to measure how well Response Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Response Oncology currently holds 26.45 M in liabilities. Response Oncology has a current ratio of 13.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Response Oncology's use of debt, we should always consider it together with its cash and equity.
Response Oncology, Inc. does not have significant operations. Prior to the sale of its assets, it provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists owned the assets of and managed the nonmedical aspects of oncology practices compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee and conducted outcomes research on behalf of pharmaceutical manufacturers. Response Oncology is traded on OTC Exchange in the United States. Response Oncology (ROIX) is traded on OTCCE Exchange in USA and employs 10 people. Management Performance
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 |
Response Oncology Leadership Team
Elected by the shareholders, the Response Oncology's board of directors comprises two types of representatives: Response Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Response. The board's role is to monitor Response Oncology's management team and ensure that shareholders' interests are well served. Response Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Response Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Sweet, President CEO | ||
| Frank Bumstead, Vice Chairman |
Response Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Response Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| Gross Profit | 28.17 M | |||
| EBITDA | 1.32 M | |||
| Net Income | (51.39 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |